The World Health Organization (WHO) recently announced that the Sabin strain (Vero cell) inactivated poliomyelitis vaccine (sIPV) developed by Sinopharm Group's Beijing Institute of Biological Products has been pre-qualified and is available for procurement by the United Nations system.

It is China's seventh domestically produced vaccine that has passed pre-qualification, which demonstrates that the regulation, development and production systems and the quality of China's vaccine products have been internationally recognized. The vaccine will also make a significant contribution to global poliomyelitis eradication.